Last reviewed · How we verify

NCT03288766: MODUS II

SHERLOCK 3CG™ Diamond Tip Confirmation System

Terminated Last updated 20 October 2021
What this trial tests

trial testing PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software in Indication for Peripheral Intravenous Catheterization in 232 participants. Terminated before completion.

Timeline
19 April 2018
Primary endpoint
15 June 2021
15 June 2021

Quick facts

Lead sponsorC. R. Bard
StatusTerminated
Study typeOBSERVATIONAL
Enrollment232
Start date19 April 2018
Primary completion15 June 2021
Estimated completion15 June 2021
Sites8 locations across United States, Australia

Drugs / interventions tested

Conditions studied

Sponsor

C. R. Bard — full company profile →

Who can join

21 and older, any sex, with Indication for Peripheral Intravenous Catheterization or Atrial Flutter. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally inserted central catheters (PICCs) in adult subjects with altered cardiac rhythm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other C. R. Bard trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing